Therapeutic options for adult T-cell leukemia/lymphoma (Q38128790)

29 August 2017

Therapeutic options for adult T-cell leukemia/lymphoma (English)

1 reference

29 August 2017

5

1 reference

29 August 2017

Ali Bazarbachi

6

0 references

author name string

Ambroise Marçais

1

1 reference

29 August 2017

Felipe Suarez

2

1 reference

29 August 2017

David Sibon

3

1 reference

29 August 2017

Laurent Frenzel

4

1 reference

29 August 2017

1 October 2013

1 reference

29 August 2017

Current Oncology Reports

1 reference

29 August 2017

15

1 reference

29 August 2017

5

1 reference

29 August 2017

457-464

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-013-0332-6

29 August 2017

0 references

cites work

Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87).

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

Long-term study of indolent adult T-cell leukemia-lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

Can allo-SCT with RIC cure ATLL? Long-term survivors with excellent PS and with heterogenous HTLV-1 proviral load level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

Controversies in targeted therapy of adult T cell leukemia/lymphoma: ON target or OFF target effects?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

Arsenic trioxyde in the treatment of HTLV1 associated ATLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

Susceptibility of human T-cell leukemia virus type I-infected cells to humanized anti-CD30 monoclonal antibodies in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

A simple p53 functional assay for screening cell lines, blood, and tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

Treatment of Adult T-Cell Leukemia-Lymphoma with Zidovudine and Interferon Alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

Meta-Analysis on the Use of Zidovudine and Interferon-Alfa in Adult T-Cell Leukemia/Lymphoma Showing Improved Survival in the Leukemic Subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

Promising results of an anti-CCR4 antibody, KW-0761, for relapsed Adult T-Cell Leukemia-Lymphoma (ATL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

Targeting HTLV-I latency in Adult T-cell Leukemia/Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0332-6

Clinical trials of adult T-cell leukaemia/lymphoma treatment

21 January 2018

1 reference

12 December 2020

The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia.

1 reference

12 December 2020

Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac.

1 reference

12 December 2020

Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells

1 reference

12 December 2020

Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group experience

1 reference

12 December 2020

A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients.

1 reference

12 December 2020

Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation.

1 reference

12 December 2020

Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia

1 reference

12 December 2020

Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting

1 reference

12 December 2020

Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study

1 reference

12 December 2020

10.1007/S11912-013-0332-6

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

0 references

1 reference